Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
21 February 2018 Photo pixabay
Water-wise expert says Is there a solution to pollution
Next time you want to throw something away, think twice. Look for ways to reuse, recycle, or repurpose.

Dr Cindé Greyling completed her PhD in Disaster Management with DiMTEC (Disaster Management Training and Education Centre for Africa) at the University of the Free State (UFS). Built on prior studies and years of communication experience, she opted to study ways in which to communicate drought mitigation information. Part of the mitigation process included saving water and reducing pollution.

A practical approach
“Look, we are all here now. And we need to eat, live, work, survive, and ultimately thrive using our planet’s resources,” she says. “But I think we’ve become so fixated on thriving, that we don’t consider survival anymore. Of course, some people do! There are wonderful projects around the world aiming at more responsible consuming, ranging from pre-loved baby clothes, to water harvesting for individual dwellings and larger compounds.” However, she understands that people may get so overwhelmed by the vast pollution problem that they consider any of their own efforts as insignificant. “That is not true. Every single bit of plastic (or cloth, glass, iron, etc.) that is recycled or repurposed, and does not end up in a landfill, makes a difference.” And here is why…

The tip of the iceberg
“Whatever you are holding in your hand and aiming for the bin is much larger than what you see. Take a piece of paper, for example. A tree was planted – the process involved fossil fuels, water, fertiliser, time, wages, administration, etc. And many years of that! Once it was felled, the resource usages continued, and expanded to processing plants, wholesalers, retailers, and then you – who also used resources to acquire that piece of paper. Do you see how large the wastage is? The same is true for food waste … that rotten tomato you forgot in the fridge is a grave loss.”

“Whatever you are holding in your hand,
aiming for the bin, is much larger what
you see.”


Little by little  
Fortunately, all is not lost. “Respect stuff,” Dr Greyling says, “it is as simple as that. To survive, we must take from the resources that the Earth provides. Because we became clever, we were able to alter these elements to make, from high-rise buildings to tiny technology. But we simply cannot keep on taking and taking without giving back Start with giving respect. Next time you want to throw something away, think twice. Look for ways to reuse, recycle, or repurpose. Consider that the denim you are wearing possibly used up to 10 000 litres of water to produce.”  

LISTEN: Dr Greyling elaborates on solutions for pollution

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept